4ZU Stock Overview
A clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Biora Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.10 |
| 52 Week High | US$23.00 |
| 52 Week Low | US$3.88 |
| Beta | 1.28 |
| 11 Month Change | 0% |
| 3 Month Change | -12.82% |
| 1 Year Change | -58.20% |
| 33 Year Change | -99.35% |
| 5 Year Change | n/a |
| Change since IPO | -99.18% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4ZU | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.7% | -0.02% |
| 1Y | -58.2% | -17.2% | 8.2% |
Return vs Industry: 4ZU underperformed the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 4ZU underperformed the German Market which returned 8.2% over the past year.
Price Volatility
| 4ZU volatility | |
|---|---|
| 4ZU Average Weekly Movement | 11.7% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 4ZU's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4ZU's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 58 | Adi Mohanty | www.bioratherapeutics.com |
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline.
Biora Therapeutics, Inc. Fundamentals Summary
| 4ZU fundamental statistics | |
|---|---|
| Market cap | €5.90m |
| Earnings (TTM) | -€34.16m |
| Revenue (TTM) | €856.59k |
6.9x
P/S Ratio-0.2x
P/E RatioIs 4ZU overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4ZU income statement (TTM) | |
|---|---|
| Revenue | US$892.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$892.00k |
| Other Expenses | US$36.47m |
| Earnings | -US$35.57m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -9.67 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,988.12% |
| Debt/Equity Ratio | -36.9% |
How did 4ZU perform over the long term?
See historical performance and comparison